The study under scrutiny, led by Thomas Ichim and colleagues and published earlier in the same journal, reported striking results from a proprietary senolytic vaccine dubbed SenoVax, used in combination with personalized mesenchymal stromal cells, or pMSCs. In mouse models of liver injury induced by carbon tetrachloride and of chemotherapy damage induced by doxorubicin, the combination therapy improved biochemical markers of organ function, reduced inflammatory signals, and enhanced physical performance. Crucially, the four-arm experimental design allowed the researchers to show that the combination outperformed either the vaccine or the cell therapy alone, suggesting a genuine synergistic interaction between the two interventions. On its face, the data looked like a textbook case of translational success: a vaccine that primes the immune system against senescent cells, paired with regenerative cells that repair damaged tissue, delivering benefits neither could achieve alone.

But Chen and Sun’s letter dismantles the leap from those observations to the conclusion that the therapy works by selectively clearing senescent cells, a process known as senolysis. Their central argument is about what scientists call target engagement, the direct demonstration that a therapy actually hits and modifies its intended biological target. SenoVax is described as an adjuvanted proprietary peptide formulation directed against senescence-associated surface antigens, yet the specific antigens were never identified in the original study. Without knowing which molecular flags the vaccine is meant to recognize, and without showing that immune recognition and depletion of a defined population of senescent cells actually occurred, the senolytic interpretation remains an assumption rather than a demonstrated mechanism.

The problem is compounded by the biomarkers the original study relied upon. The researchers measured circulating levels of interleukin-6, interleukin-11, YKL-40 and interleukin-23 receptor signaling, molecules that are indeed associated with the senescence-associated secretory phenotype, the inflammatory cocktail that aged and damaged cells release into their surroundings. But these same molecules are notoriously promiscuous. They rise in response to tissue injury, general inflammation and immune modulation of many kinds. A fall in these circulating markers after vaccination, after pMSC infusion, or after the combination cannot distinguish between the removal of senescent cells and simply reduced injury or altered cytokine production by other cell types. In other words, the biomarkers are consistent with senolysis but equally consistent with several alternative explanations, and the study design provided no way to separate them.

This is not a fringe objection. Chen and Sun anchor their critique in the field’s own consensus standards, citing guidelines for minimal information on cellular senescence experimentation in vivo published in Cell in 2024, as well as the landmark 2019 consensus statement on defining cellular senescence. Those guidelines recommend convergent lines of evidence, including lineage-resolved markers that identify which cells are senescent, proof of stable cell-cycle arrest, and, critically, direct validation that an intervention actually removes the specific cells to which the therapeutic benefit is attributed. The original study, by its authors’ own acknowledgment, lacked p16INK4a staining and senescence-associated beta-galactosidase assays, two of the most widely used markers of cellular senescence. The letter’s authors argue this is far more than a request for an additional stain on a slide.

Without pre-specified cellular targets, same-cell phenotyping before treatment, and quantitative measurement of the loss of those cells after SenoVax administration, senolysis simply is not a demonstrated mechanism. Chen and Sun point out that the observed synergistic benefit could arise entirely from independent immunomodulatory and trophic effects of the two therapies, with the magnitude of the interaction telling us nothing about which biological pathway produced it. To make the mechanism reproducible and falsifiable, they propose a concrete experimental checklist: disclosure of the vaccine antigens, control groups receiving irrelevant-peptide vaccinations, direct measurements of immune responses, ex vivo cytotoxicity assays testing whether immune cells from treated animals kill senescent but not non-senescent primary cells, and tissue-level demonstration that the targeted cell population is actually depleted. Each of these is a standard tool in immunology, and none is technically exotic, which makes their absence all the more consequential.

The second half of the letter takes aim at the language of longevity itself. The survival experiment in the original study began with 12-week-old mice, young adults in mouse terms, that were then exposed to doxorubicin three times weekly until death. What that design measures, Chen and Sun insist, is survival under sustained chemotherapy toxicity, not lifespan across the natural arc of ageing. A treatment can mitigate drug toxicity, dampen inflammation or protect organs from injury without touching the ageing process itself. Calling such an outcome lifespan extension, they argue, imports a geroscience claim that the experiment was never built to test. The same logic applies to the functional measures: liver enzymes such as AST and ALT and a pole test of neuromuscular performance are valuable disease and performance endpoints, but they do not by themselves establish healthspan, the period of life spent free of age-related disease and decline, in the sense that geroscientists use the term.

The letter also flags a discrepancy that any careful reader of the original paper would find troubling. The methods section of the original study describes doxorubicin dosing at 2 milligrams per kilogram once weekly for four weeks, while figures 6 and 7 of the same article state 5 milligrams per kilogram three times weekly. Chen and Sun call for this inconsistency to be clarified before the survival and functional results can be reproduced by other laboratories. In a field where dosing regimens determine both toxicity and any putative benefit, such ambiguity is not a trivial typographical issue; it strikes at the reproducibility of the central claims.

What makes this exchange particularly significant is what it says about the trajectory of the senescence field as a whole. Cellular senescence has become one of the most commercially attractive concepts in biomedicine, with senolytic drugs, senomorphic compounds and now senolytic vaccines attracting substantial investment and breathless media coverage. The promise is enormous: if the accumulation of dysfunctional senescent cells drives ageing and age-related disease, then clearing them could extend not just lifespan but healthspan. But the field’s own thought leaders have repeatedly warned that enthusiasm is outrunning evidence, and the Chen and Sun letter is a precise, technical articulation of exactly where the evidentiary gaps lie. A therapy can be genuinely beneficial, as the combination data in two injury models suggest, without being senolytic, and it can extend survival under toxic challenge without extending life in any meaningful anti-ageing sense.

The constructive path forward, as the letter makes clear, is not to abandon the approach but to test it properly. Direct, lineage-resolved target-engagement studies would show whether SenoVax actually eliminates senescent cells in living tissue, and survival experiments in naturally ageing cohorts, animals allowed to grow old without continuous chemotherapy exposure, would reveal whether the intervention modifies ageing itself rather than merely buffering a drug’s side effects. Until those experiments are done, Chen and Sun argue, the study provides preliminary evidence of combination benefit in two injury models, but not yet of senescent-cell-selective immunotherapy or lifespan extension. For a field racing toward human trials, that distinction is not pedantry. It is the difference between a therapy that treats damage and one that treats time, and only rigorous, falsifiable science can tell them apart.

Subject of Research: Critique of senolytic vaccine and mesenchymal stromal cell combination therapy claims in mouse models of tissue injury and chemotherapy toxicity

Article Title: Treatment benefit does not establish senolysis or lifespan extension

Article References: Chen, W., & Sun, X. (2026). Treatment benefit does not establish senolysis or lifespan extension. Journal of Translational Medicine, 24(1), Article 1251. https://doi.org/10.1186/s12967-026-09014-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09014-z

Keywords: cellular senescence, senolytics, SenoVax, mesenchymal stromal cells, target engagement, lifespan extension, healthspan, doxorubicin, senescence-associated secretory phenotype, geroscience, Journal of Translational Medicine, reproducibility

Interoception, the central concept in the new analysis, is commonly defined as the process by which the nervous system senses, interprets, and integrates signals arising from within the body. Heartbeat, breathing rhythm, temperature, visceral tension, and the constellation of internal sensations that color every waking moment all travel upward through dedicated neural channels. The authors emphasize that a substantial portion of this traffic passes through the spinal cord, forming what they call spinal interoceptive pathways. These pathways deliver continuous updates about bodily states to a distributed interoceptive system in the brain, where they inform and constrain predictive models of what the body will experience next. In this framework, the brain is not a passive receiver but an active forecaster, constantly generating predictions about upcoming bodily states and comparing them against incoming signals.

The predictive dimension is where interoception connects most directly to emotion. According to the theoretical models reviewed by Romo-Nava and his colleagues, the brain uses its predictions about bodily states to adjust physiology through descending projections, a closed-loop architecture that maintains homeostasis—the finely tuned internal equilibrium on which survival depends. Emotional experience, in this view, is inseparable from the quality and accuracy of the bodily signals feeding the loop. When the ascending traffic is distorted, dampened, or amplified, the brain’s predictive models drift out of alignment with actual bodily conditions, and the subjective result may be the persistent malaise, heaviness, and dysphoria characteristic of depression. The authors argue that dysregulated signaling in spinal interoceptive pathways and the resulting interoceptive processing errors may play a genuine role in the depressive syndrome rather than being a mere byproduct of it.

What makes this proposal more than a philosophical reframing is its therapeutic implication. If the spinal cord carries a continuous stream of body-to-brain information that shapes mood, then the spinal cord is a physically accessible target. Unlike dispersed cortical networks buried deep within the brain, spinal pathways run through an anatomically well-mapped structure that clinicians already know how to stimulate, record from, and modulate. Neuromodulation technologies—devices and techniques that alter nerve activity through targeted electrical or other stimulation—are routinely applied to the spinal cord in other areas of medicine, most famously for pain management. The perspective article argues that the same general strategy could, in principle, be redirected toward the interoceptive traffic that informs emotional state, opening a novel route for studying and eventually treating major depressive disorder.

The scale of the unmet need gives the proposal urgency. Major depressive disorder affects hundreds of millions of people worldwide, and a large fraction of patients do not achieve lasting relief from available medications and psychotherapies. Existing neuromodulation treatments for depression, such as transcranial magnetic stimulation and implanted brain stimulation devices, work from the top of the loop, targeting the brain directly. An approach that intervenes from the bottom of the loop, at the spinal gateway where bodily signals enter, would represent a fundamentally different mechanistic strategy—one that could complement rather than compete with brain-focused therapies. The authors position spinal interoceptive modulation not as a replacement for existing care but as an additional lever on a system that current treatments leave largely untouched.

Yet the researchers are candid about a major obstacle: a substantial knowledge gap. Despite the theoretical appeal of the framework, the role of spinal interoceptive pathways in major depressive disorder remains poorly characterized. It is not yet established which specific spinal mechanisms are altered in depression, how those alterations propagate to the distributed interoceptive system in the brain, or how changes in spinal signaling correlate with changes in mood. The perspective article frames this gap as the central scientific challenge of the field and argues that closing it requires deliberate experimentation rather than assumption. The authors present their work as emerging evidence supporting the exploration of spinal interoceptive pathways as novel and feasible targets—emphasizing both words, novelty and feasibility, to signal that the approach is grounded in existing technology while pointing toward unexplored biology.

A key methodological problem the article confronts is how to prove that a spinal intervention is actually doing what it claims to do. In clinical neuroscience, this is the problem of target engagement: demonstrating that a treatment measurably modifies the biological mechanism it is designed to influence. Without reliable markers of spinal interoceptive target engagement, any clinical trial of spinal neuromodulation for depression would be flying blind, unable to distinguish between a therapy that failed because the mechanism was wrong and one that failed because the delivery was imprecise. The authors therefore devote significant attention to candidate experimental models and the critical next steps needed to identify markers that would show whether a given intervention is genuinely changing spinal interoceptive signaling. Such markers would be the measurement backbone for future studies, allowing researchers to connect stimulation parameters to physiological changes and physiological changes to clinical outcomes.

The research program described in the article is already backed by institutional investment. The work was supported by the Lindner Center of Hope and the University of Cincinnati, as well as by the National Institute of Mental Health, which funded the effort in part through grant 1R61MH133770-01A1. The breadth of the author team reflects the interdisciplinary demands of the project: the collaboration includes psychiatrists, neurologists, neurosurgeons, a biostatistician, and interoception specialists from the Laureate Institute for Brain Research and UCLA’s Semel Institute for Neuroscience and Human Behavior. Bringing together expertise in spine-level intervention, brain imaging, psychiatric assessment, and trial design is a prerequisite for a program that spans the length of the neuraxis—from peripheral bodily sensors through spinal relay stations to cortical interoceptive networks.

The broader scientific context makes the timing of this proposal notable. Across neuroscience, interoception has moved from a niche topic to a central framework for understanding psychiatric illness, with conditions including anxiety, eating disorders, and depression increasingly interpreted as disorders of bodily signal processing. Predictive processing models of the brain have given the field a common theoretical language, describing perception and emotion as consequences of prediction and prediction error rather than simple stimulus response. The spinal cord, in this emerging picture, is no longer a mere cable between brain and body but an active processing station that shapes the information it transmits. The Romo-Nava perspective extends that shift by insisting that the clinical implications run in both directions: just as the brain constrains the body through descending projections, the body constrains the brain through ascending spinal channels, and either side of the loop can be an intervention point.

If the research program succeeds, the consequences could extend well beyond depression. Spinal interoceptive pathways plausibly contribute to the physical symptoms that accompany many psychiatric conditions—chronic pain, fatigue, autonomic dysregulation—and a validated method for measuring and modulating spinal interoceptive signaling could illuminate all of them. For now, the authors’ contribution is a roadmap: a reasoned case that the spinal cord is a feasible, mechanistically motivated target for depression research, an honest account of what remains unknown, and a set of candidate models and engagement markers to guide the experiments ahead. As the field confronts the limits of treatments aimed solely at the brain, the message of this perspective is that mood may be built, in part, from signals that begin their journey in the body—and that the gateway through which those signals travel may one day become a place where depression is treated.

Subject of Research: The role of spinal interoceptive pathways in major depressive disorder and their potential as neuromodulation targets

Article Title: Spinal interoceptive pathways as therapeutic targets in depression

Article References: Romo-Nava, F., Awosika, O. O., Phan, P., Basu, I., Liu, J. C., Charnas, C., Georgiev, G., Mori, N. N., Welge, J., Blom, T., Fleck, D. E., Cao, X., Khalsa, S., Paulus, M., & McElroy, S. L. (2026). Spinal interoceptive pathways as therapeutic targets in depression. Discover Mental Health. https://doi.org/10.1007/s44192-026-00597-z

Image Credits: AI Generated

DOI: 10.1007/s44192-026-00597-z

Keywords: interoception, spinal cord, major depressive disorder, neuromodulation, predictive processing, homeostasis, psychiatry, spinal interoceptive pathways, target engagement, neuroscience, Spinal, interoceptive